GeoVax Announces $10 Million Private Placement

ATLANTA, GA, January 14, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded…

Read More

CMS’ Attempt to Restrict Patient Access to Alzheimer’s Drug Sets “Dangerous and Far-Reaching” Precedent

Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) to restrict coverage for drugs used to treat patient suffering from Alzheimer’s: “The announcement by CMS sets a dangerous and far-reaching precedent for…

Read More

GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer

ATLANTA, GA, January 11, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Company’s Chief Medical Officer (CMO). Dr. McKee brings over 30 years of experience in research and development, with…

Read More

GeoVax Receives Notice of Allowance for Ebola Vaccine Patent

Single-dose of GEO-EM01 Provided 100% Protection in Lethal Challenge Evaluation ATLANTA, GA, October 14, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 15/543,139 entitled “Replication-Deficient…

Read More

Quorum X Diagnostics Inc., (QXD) is awaiting FDA Emergency Use Authorization for its 4-minute At-Home COVID Antigen Test called COVIDNOW®

Tucker, GA— April 17, 2021 —Quorum X Diagnostics, Inc. (QXD) has announced that it is awaiting Emergency Use Authorization (EUA) approval by the U.S. FDA for the first, 4-minute at-home COVID antigen test named COVIDNOW®.  This test is available without prescription. “We have every confidence that our EUA will be approved,” said CEO and Co-founder, Dr. Maria M. Nagy, “we…

Read More

Half of US adults have received at least one COVID-19 shot

WASHINGTON (AP) — Half of all adults in the U.S. have received at least one COVID-19 shot, the government announced Sunday, marking another milestone in the nation’s largest-ever vaccination campaign but leaving more work to do to convince skeptical Americans to roll up their sleeves. Almost 130 million people 18 or older have received at…

Read More

US setting up $1.7B national network to track virus variants

WASHINGTON (AP) — The U.S. is setting up a $1.7 billion national network to identify and track worrisome coronavirus mutations whose spread could trigger another pandemic wave, the Biden administration announced Friday. White House officials unveiled a strategy that features three components: a major funding boost for the Centers for Disease Control and Prevention and state health…

Read More